HomeCompareHTLZF vs ARCC

HTLZF vs ARCC: Dividend Comparison 2026

HTLZF yields 125.78% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HTLZF wins by $10.58M in total portfolio value
10 years
HTLZF
HTLZF
● Live price
125.78%
Share price
$1.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10.60M
Annual income
$4,136,135.42
Full HTLZF calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — HTLZF vs ARCC

📍 HTLZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHTLZFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HTLZF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HTLZF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HTLZF
Annual income on $10K today (after 15% tax)
$10,691.15/yr
After 10yr DRIP, annual income (after tax)
$3,515,715.11/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, HTLZF beats the other by $3,515,714.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HTLZF + ARCC for your $10,000?

HTLZF: 50%ARCC: 50%
100% ARCC50/50100% HTLZF
Portfolio after 10yr
$5.31M
Annual income
$2,068,068.28/yr
Blended yield
38.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

HTLZF
No analyst data
Altman Z
4.0
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HTLZF buys
0
ARCC buys
0
No recent congressional trades found for HTLZF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHTLZFARCC
Forward yield125.78%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$10.60M$24.5K
Annual income after 10y$4,136,135.42$1.14
Total dividends collected$9.68M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: HTLZF vs ARCC ($10,000, DRIP)

YearHTLZF PortfolioHTLZF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$23,278$12,577.83$11,373$532.74+$11.9KHTLZF
2$52,270$27,363.03$12,608$279.46+$39.7KHTLZF
3$113,353$57,423.94$13,809$142.90+$99.5KHTLZF
4$237,670$116,382.56$15,042$72.20+$222.6KHTLZF
5$482,366$228,058.17$16,341$36.27+$466.0KHTLZF
6$948,708$432,576.52$17,732$18.18+$931.0KHTLZF
7$1,810,242$795,124.80$19,231$9.10+$1.79MHTLZF
8$3,354,892$1,417,933.12$20,851$4.55+$3.33MHTLZF
9$6,045,653$2,455,918.14$22,605$2.28+$6.02MHTLZF
10$10,604,984$4,136,135.42$24,504$1.14+$10.58MHTLZF

HTLZF vs ARCC: Complete Analysis 2026

HTLZFStock

Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. It offers precision laser systems, imaging systems, and other equipment and consumables for the ART and developmental biology research markets under the Hamilton Thorne brand; test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services under the Embryotech brand. The company also manufactures and distributes products for reproductive medicine, including clinical and laboratory equipment and disposables, as well as complete installations of ART clinics under the Gynemed brand; and bench top incubators, programmable freezers, loggers, alarms, cryo storage, and software systems and sensors for the safe preservation of medical and biological specimens used in ART and cell biology applications under the Planer brand. It sells its products and services through a direct sales force in the United States, Germany, France, and the United Kingdom, as well as through distributors to approximately 2,000 fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 75 countries. The company is headquartered in Beverly, Massachusetts.

Full HTLZF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this HTLZF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HTLZF vs SCHDHTLZF vs JEPIHTLZF vs OHTLZF vs KOHTLZF vs MAINHTLZF vs HTGCHTLZF vs GBDCHTLZF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.